Gen Brands Norton, Avast, AVG and Avira Earn 16 Award Recognitions Across Third-Party Testing Institutions AV-Comparatives, AV-Test, and AVLab
TEMPE, Ariz. and PRAGUE, April 3, 2025 /PRNewswire/ -- Gen (NASDAQ: GEN), a global leader dedicated to powering Digital Freedom, today announced that independent testing institutions AV-Comparatives, AV-Test and AVLab have recognized multiple products across Gen trusted consumer brands: Norton, Avast, AVG and Avira.
'We recognize the rigor of these tests and are honored to receive awards from three of the leading cybersecurity benchmarking institutions,' said Siggi Stefnisson, Cyber Safety CTO at Gen. 'The threat landscape is changing at a rapid pace, and our team works tirelessly to adjust both our core technology and our products to ensure our customers are protected from the latest threats, year after year.'
During the testing process, cybersecurity products go through structured evaluations that measure real-world protection, malware defense, and overall performance. The recognition from these independent testing labs across four Gen brands highlights the company's industry-leading technology, powered by advanced machine learning and AI capabilities.
'At Gen, we are committed to delivering the industry's most innovative Cyber Safety solutions, that address people's unique needs in an ever-changing threat landscape. This recognition reinforces the impact and peace of mind we always strive to provide our customers,' said Leena Elias, Chief Product Officer at Gen. 'These awards from independent labs further validate the trust in our technology.'
Gen Brands Recognized for 'Top Rated Products'
AV-Comparatives named Avast and AVG 'top rated products,' awarding Gold to Avast, AVG and Avira for Real World Protection, Bronze to Avast for Malware Protection and Bronze Avast and AVG for Advanced Threat Protection. The institute also awarded Norton, Avast and AVG for 'Outstanding Protection Against Fake Online Shops'.
Norton, Avast and AVG were additionally recognized as the Best MacOS Security for home users by AV-Test, and AVLab recognized Avast Free Antivirus as winner of the Product of the Year award for its advanced in-the-wild malware protection test as well as recognizing the product for Top Remediation Time.
Andreas Clementi, CEO of AV-Comparatives said, 'Our testing process is designed to objectively evaluate product performance under real-world conditions. Gen's products met the criteria for top recognition in multiple categories, indicating reliable security performance across their consumer portfolio.'
About Gen
Gen™ (NASDAQ: GEN) is a global company dedicated to powering Digital Freedom through its trusted Cyber Safety brands, Norton, Avast, LifeLock, Avira, AVG, ReputationDefender and CCleaner. The Gen family of consumer brands is rooted in providing safety for the first digital generations. Now, Gen empowers people to live their digital lives safely, privately, and confidently today and for generations to come. Gen brings award-winning products and services in cybersecurity, online privacy and identity protection to nearly 500 million users in more than 150 countries. Learn more at .
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
Drug maker Indivior joins the flight from London share listings
Drug maker Indivior has become the latest major UK listed company to scrap its London share trading. The pharmaceuticals company, which has its UK headquarters in Slough, said it planned to cancel its secondary listing in London. Indivior only moved its primary listing to Nasdaq last June and now wants to sever all share trading links with the City. The move comes just a year after Invidior's board said it planned to keep the London listing "for as long as it is considered to be in the best interests of Indivior and its shareholders as a whole." Reasons given for scrapping the London listing following a review include the fact that 80% of the company's revenue is generated in America; trading on Nasdaq accounts for approximately 75% of total volumes across both exchanges; more than 70% of the share are now held by investors located in the U.S; and the elimination of 'the cost and complexity of maintaining a secondary listing.' Another major factor is that the company's biggest selling drug Sublocade, a treatment for helping opioid addicts reduce their dependence, has its biggest market in the US. Last year Sublocade accounted for $756 million of the company's total $1.2 billion sales. Indivior was spun out of its former parent company, the consumer products giant Reckitt Benckizer in 2014 as a free standing London listed company. The Virginia based company's chair David Wheadon, said:"We are pleased to announce this key milestone for Indivior following our evaluation period. A single primary listing on Nasdaq best reflects the profile of Indivior's business. 'We appreciate the support received from shareholders for this initiative and look forward to capitalizing on the expected benefits of this move, including reductions in cost and complexity." London has suffered a major outflow of listed companies over recent years in a blow to the prestige of the City. A total of 88 firms delisted or transferred their primary listing from the London Stock Exchange last year, the highest number since the financial crisis of 2008, according to auditor EY. Only 18 companies came on to the London market last year as the vital flow of small and growing businesses raising capital by listing their shares on the London stock market dried up. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Indivior to delist from London Stock Exchange, maintain Nasdaq listing
(Reuters) -Pharma firm Indivior said on Monday it will cancel its secondary listing on the London Stock Exchange, effective July 25, maintaining its primary listing on the Nasdaq to reduce costs and better align with its U.S.-centric business. The company, known for its opioid addiction treatment, joins a growing number of companies delisting from London, as lower valuations and weak investor appetite continue to drive firms toward U.S. markets. Shares of Indivior, which floated in London in late 2014, have dropped more than 60% from record highs hit in June 2018. The company said over 80% of its revenue now comes from the U.S., with the Nasdaq accounting for about 75% of recent trading volumes. The delisting aims to streamline operations and reflect the company's strategic focus on the U.S. market, it said. Indivior moved its primary listing to the United States last year. The decision to delist from London comes just months after Indivior overhauled its management. Earlier this year, it appointed David Wheadon as chair and Joe Ciaffoni as CEO. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
an hour ago
- Business Insider
‘Keep on Buying,' Says Morgan Stanley About Tesla Stock
Tesla (NASDAQ:TSLA) stock is back in focus as Elon Musk shifts gears, stepping away from political headlines and returning his attention to the company that made him a household name. Confident Investing Starts Here: The move was no doubt greeted enthusiastically by Tesla investors, who have grown frustrated with Musk's high-profile distractions since becoming Trump's 'first buddy.' But beyond the optics, Morgan Stanley analyst Adam Jonas, a longtime Tesla bull, believes there's more at stake, pointing to broader strategic implications tied to Musk's renewed commitment. 'In our view,' Jonas noted, 'Tesla's expertise in manufacturing, data collection, robotics/ physical AI, energy, supply chain and infrastructure are more critical than ever before to put the US on an even footing with China in embodied AI.' Jonas points to China's rapid progress in humanoid robotics – what he calls the 'Humanoid Olympics.' After showcasing robots running a half marathon and competing in combat sports, China is now moving toward full-on humanoid games. 'China's gamification of robotic innovation is accelerating its path to AI supremacy,' says Jonas, who wonders if the US should fight back with a 'Humanoid Ninja Warrior.' The specter of Chinese EV maker BYD looms large too. The company announced significant price reductions across its entire lineup recently – ranging from 10% to nearly 30%. Notably, the price of its budget-friendly Seagull model was slashed to just RMB 55,800 (under $8,000). 'If you want evidence of the 'race to the bottom' in global EV prices, look no further,' says Jonas. The analyst also wonders if Musk might be having a change of heart regarding one possible business venture. For years, he has dismissed the idea of Tesla building eVTOLs or drones, pointing to concerns like noise, privacy issues, public nuisance, and inadequate battery energy density. However, during a recent all-hands meeting, when asked about the possibility of making a plane, Musk paused before replying that the company is currently 'stretched pretty thin.' 'In our opinion,' says Jonas, 'that's a decidedly different type of answer. Is Tesla an aviation/defense-tech company in auto/consumer clothing?' As for the upcoming Cybercab launch, slated for June 12, as with most highly anticipated Tesla events, Jonas thinks it's best to keep a lid on expectations. That said, he'll be watching closely for ongoing updates in the following days and weeks – particularly regarding network performance and growth metrics like vehicle count, mileage, and trip volume. All in all, Jonas remains on TSLA's side, assigning an Overweight (i.e., Buy) rating with a $410 price target, implying potential upside of 18% from current levels. (To watch Jonas's track record, click here) That's a bull's take, but not one the majority of Wall Street analysts share; TSLA stock only claims a Hold consensus rating, based on a mix of 16 Buys, 10 Holds and 11 Sells. Going by the $282.70 average price target, a year from now, shares will be changing hands for an 18% discount. (See TSLA stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.
